Please wait a minute...
文章检索
预防医学  2021, Vol. 33 Issue (1): 31-34    DOI: 10.19485/j.cnki.issn2096-5087.2021.01.007
  论著 本期目录 | 过刊浏览 | 高级检索 |
安徽省上消化系统疾病患者CYP2C19基因多态性研究
吴黎黎1, 张素梅2, 邵璇璇1, 章宝芝1, 赵寅生1
1.中国人民解放军联勤保障部队第901医院检验科,安徽 合肥 230001;
2.安徽医科大学生物化学与分子生物学教研室
Analysis of CYP2C19 gene polymorphism in patients with upper digestive system diseases in Anhui Province
WU Lili, ZHANG Sumei, SHAO Xuanxuan, ZHANG Baozhi, ZHAO Yinsheng
Department of Clincal Laboratory, The 901st Hospital of Combined Service Force of People's Liberation Army, Hefei, Anhui 230001, China
全文: PDF(859 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解安徽省307例上消化系统疾病患者CYP2C19基因的多态性,为上消化系统疾病个性化治疗提供依据。方法 选取中国人民解放军联勤保障部队第901医院消化科就诊的307例上消化系统疾病患者为研究对象。采用DNA微阵列基因芯片法检测CYP2C19基因型,分析不同性别、年龄和病种患者的CYP2C19基因型和代谢型。结果 研究对象年龄为(58.00±16.13)岁。男性197例,占64.17%;女性110例,占35.83%。CYP2C19*1型、CYP2C19*2型和CYP2C19*3型基因频率分别为62.70%、32.25%和5.05%。基因型*1/*1(636GG,681GG)119例,占38.76%;*1/*2(636GG,681GA)129例,占42.02%;*1/*3(636GA,681GG)18例,占5.86%;*2/*2(636GG,681AA)29例,占9.45%;*2/*3(636GA,681GA)11例,占3.58%;*3/*3(636AA,681GG)1例,占0.33%。快代谢型119例,占38.76%;中间代谢型147例,占47.88%;慢代谢型41例,占13.35%。不同性别、年龄、病种患者的CYP2C19基因型和代谢型分布差异均无统计学意义(P>0.05)。结论 上消化系统疾病患者CYP2C19基因型存在多态性,以快代谢型和中间代谢型为主,可为质子泵抑制剂个体化治疗的临床用药提供参考。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
吴黎黎
张素梅
邵璇璇
章宝芝
赵寅生
关键词 上消化系统疾病CYP2C19基因型代谢型    
AbstractObjective To analyze the CYP2C19 gene polymorphism in patients with upper digestive system diseases in Anhui Province, so as to provide evidence for individual treatment. Methods The 307 patients with upper digestive system diseases in the Department of Gastroenterology, The 901st Hospital of Combined Service Force of People's Liberation Army were selected. The CYP2C19 genotypes were detected by DNA microarray microarray. The CYP2C19 genotypes and metabolic types in different genders, ages and diseases were analyzed. Results There were 197 males ( 64.17% ) and 110 females ( 35.83% ) , with the age of ( 58.00±16.13 ) years old. The gene frequency of CYP2C19*1, CYP2C19*2 and CYP2C19*3 was 62.70%, 32.25% and 5.05%, respectively. There were 119 cases (38.76%) of *1/*1 ( 636GG, 681GG ), 129 cases ( 42.02% ) of *1/*2 ( 636GG, 681GA ) , 18 cases (5.86%) of *1/*3 ( 636GA, 681GG ) , 29 cases ( 9.45% ) of *2/*2 ( 636GG, 681AA ) , 11 cases ( 3.58% ) of *2/*3 ( 636GA, 681GA ) , and 1 cases ( 0.33% ) of *3/*3 ( 636AA, 681GG ). In terms of metabolisms, there were 119 cases ( 38.76% ) of fast metabolism type, 147 cases (47.88%) of intermediate metabolism type and 41 cases (13.35%) of slow metabolism type. There were no significant differences in CYP2C19 genotypes and metabolic types among the patients with different gender, age and digestive system diseases ( P>0.05 ).Conclusion The CYP2C19 genotypes of patients with upper digestive system diseases were polymorphic, mainly the fast metabolism type and the intermediate metabolism type, which could provide reference for the clinical medication of individualized treatment of proton pump inhibitors.
Key wordsupper digestive system diseases    CYP2C19    genotype    metabolic type
收稿日期: 2020-07-14      修回日期: 2020-09-24      出版日期: 2021-01-10
中图分类号:  R573  
基金资助:国家自然科学基金面上项目(1708085)
通信作者: 章宝芝,E-mail:393868768@qq.com   
作者简介: 吴黎黎,硕士,主管技师,主要从事分子免疫学工作
引用本文:   
吴黎黎, 张素梅, 邵璇璇, 章宝芝, 赵寅生. 安徽省上消化系统疾病患者CYP2C19基因多态性研究[J]. 预防医学, 2021, 33(1): 31-34.
WU Lili, ZHANG Sumei, SHAO Xuanxuan, ZHANG Baozhi, ZHAO Yinsheng. Analysis of CYP2C19 gene polymorphism in patients with upper digestive system diseases in Anhui Province. Preventive Medicine, 2021, 33(1): 31-34.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2021.01.007      或      http://www.zjyfyxzz.com/CN/Y2021/V33/I1/31
[1] 彭净,刘卫.CYP2C19基因多态性对药物代谢影响的研究进展[J].药学实践杂志,2015,33(6):508-512.
[2] 陈晖,蔡泓敏,冯瑞浩,等. CYP2C19CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展[J].中国药物应用与监测,2014,11(4):240-244.
[3] 蒋兴然,张云岗,路军,等.北方地区汉族消化系统疾病中CYP2C19基因多态性分析[J].临床与实验病理学杂志,2016,32(10):1101-1104.
[4] PROBST SCHENDZIELORZ K,VIVIANI R,STINGL J C.Effect cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors[J].Expert Opin Drug Metab Toxicol,2015,11(8):1219-1224.
[5] 余龙辉,周洁,叶舒慧,等.江西地区心脑血管患者CYP2C19基因多态性检测[J].安徽医科大学学报,2019,54(3):462-465.
[6] MARTIS S,PETER I,HULOT J S,et al.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes[J].Pharmacogenomics J,2013,13(4):369-374.
[7] DE KESEL P M,LAMBERT W E,STOVE C P.Alternative sampling strategies for cytochrome P450 phenotyping[J].Clin Pharamacokinet,2016,55(2):169-184.
[8] 任凌雁,袁军,陈琨,等.消化道溃疡患者奥美拉唑代谢相关基因CYP2C19的多态性分布[J].贵阳医学院学报,2015,40(10):1051-1053.
[9] 张爱玲,胡欣,杨莉萍.亚洲健康人群CYP2C19基因型发生率的合并分析[J].中国循证医学杂志,2014,14(4):427-434.
[10] 李洁,程莜雯,汪波,等.安徽汉族冠心病患者CYP2C19基因多态性研究[J].安徽医科大学学报,2018,53(5):784-788.
[11] SYCHEV D A,DENISENKO N P,SIZOVA Z M,et al.The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors[J].Pharmgenomics Pers Med,2015,79(8):111-114.
[12] GENOMES PROJECT C,ABECASIS G R,AUTON A,et al.An integrated map of genetic variation from 1092 human genomes[J].Nature,2012,491(7422):56-65.
[13] CASTRO DE GUERRA D,FLORES S,IZAGUIRRE M H.Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture[J].Ann Hum Biol,2013,40(2):197-200.
[14] 袁芳,李岚,张玲玲.CYP2C19基因多态性对不同PPI治疗Hp阳性消化性溃疡患者临床效果的影响[J].贵州医药,2018,42(7):798-800.
[15] 盛碧,陈永刚,王慧娟,等.武汉地区314例消化系统疾病患者CYP2C19基因多态性分析[J].中国现代医学杂志,2019,29(2):92-96.
[16] 郑松柏,姚健风. 老年人质子泵抑制剂合理应用专家共识[J].中华老年医学杂志,2015,16(2):1045-1052.
[17] ICHIKAWA H,SUGIMOTO M,SUGIMOTO K,et al.Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis[J].J Gastroenterol Hepatol,2015,31(4):716-726.
[18] JAINAN W,VILAICHONE R K.Effects of the CYP2C19 genetic polymorphism on gastritis,peptic ulcer disease,peptic uncler bleeding and gastric cancer[J].Asian Pac J Cancer Prev,2014,15(24):10957-10960.
[19] DENISENKO N P,SYCHEV D A,ZHM S,et al.High frequency of CYP2C19 ultrarapid metabolizers in russian patients with peptic ulcer[J].Eksp Klin Gastroenterol,2015,3(6):11-15.
[20] SAITO Y,SERIZAWA H,KATO Y,et al.First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype[J].World J Gastroenterol,2015,21(48):13548-13554.
[1] 刘丽迎, 康文娟, 董勤, 张晓刚, 阎亚琼. 53例苯丙酮尿症新生儿体格、智力和基因特征[J]. 预防医学, 2022, 34(9): 955-958.
[2] 杨茹莱, 沈亚平, 陈迟, 周莹, 徐艳华, 舒强. 2009—2021年浙江省新生儿遗传代谢病基因型分析[J]. 预防医学, 2022, 34(8): 760-764.
[3] 蒋卓婧, 葛小萍, 陈金堃, 王吉玲. 绍兴市手足口病病毒型别检测结果分析[J]. 预防医学, 2022, 34(5): 507-510.
[4] 翁正军, 陈波, 朱婧, 陈莫娇. 义乌市3起学校诺如病毒急性胃肠炎疫情的病原分子流行病学特征[J]. 预防医学, 2021, 33(3): 289-291.
[5] 叶静芬, 方晴, 胡耀仁, 许小敏, 车洋. 北京基因型耐多药结核分枝杆菌二线抗结核药物耐药基因突变特征分析[J]. 预防医学, 2021, 33(10): 983-987.
[6] 阮尉月清, 刘家法, 张米, 李健健, 杨壁珲, 邓雪媚, 董兴齐. 云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析[J]. 预防医学, 2020, 32(10): 987-991.
[7] 邢洁, 朱笕青, 于爱军, 郑爱文. 浙江省高危HPV基因型分布热力图分析[J]. 预防医学, 2019, 31(8): 851-853.
[8] 蒋雪峰, 陆晓娟, 郭林杰, 朱音, 陆叶. 浙江省首起D8基因型麻疹暴发调查[J]. 预防医学, 2018, 30(8): 819-821,824.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed